Suk-Hyung Kwon
Algemeen Directeur bij NOVAREX CO.,LTD.
Vermogen: 25 M $ op 30-04-2024
Profiel
Suk-Hyung Kwon is currently the Chairman & Chief Executive Officer at NOVAREX Co., Ltd.
since 2019.
He is also the Chief Executive Officer at NOVAKMED since 2017 and the Chairman of the Korea Health Supplements Association since 2016.
Additionally, Dr. Kwon is a Senior Associate at STIC Investments, Inc. (South Korea).
Previously, he worked as a Director at Rexahn Pharmaceuticals, Inc. from 2001 to 2005.
Dr. Kwon holds a doctorate degree from Chung-Ang University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NOVAREX CO., LTD.
17.83% | 20-05-2024 | 3 344 214 ( 17.83% ) | 25 M $ | 30-04-2024 |
Actieve functies van Suk-Hyung Kwon
| Bedrijven | Functie | Begin |
|---|---|---|
| NOVAREX CO.,LTD. | Algemeen Directeur | 22-03-2019 |
| NOVAKMED | Algemeen Directeur | 02-01-2017 |
| Korea Health Supplements Association | Voorzitter | 25-02-2016 |
STIC Investments, Inc. (South Korea)
 STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Private Equity Analist | - |
Eerdere bekende functies van Suk-Hyung Kwon
| Bedrijven | Functie | Einde |
|---|---|---|
| REXAHN PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 14-06-2005 |
Opleiding van Suk-Hyung Kwon
| Chung-Ang University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NOVAREX CO.,LTD. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
| NOVAKMED | |
| Korea Health Supplements Association | |
STIC Investments, Inc. (South Korea)
STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Finance |
